Skip to content

Comparing Virtual Reality (VR) to Non-VR for Decreasing Preoperative/Procedural Anxiety

Randomized Pilot Crossover Study Comparing Virtual Reality (VR) and Non-VR Distraction for Decreasing Preoperative/Procedural Anxiety as a Function of the Modified Yale Preoperative Anxiety Scale (mYPAS)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05094141
Enrollment
89
Registered
2021-10-26
Start date
2021-01-13
Completion date
2024-05-14
Last updated
2025-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preoperative Anxiety

Keywords

virtual reality, preoperative anxiety, modified Yale Preoperative Anxiety Scale

Brief summary

The primary objective of the study is to utilize the modified Yale Preoperative Anxiety scale (mYPAS), a validated preoperative/procedural anxiety score, to measure preoperative anxiety via distraction in pediatric oncology patients undergoing port access. The hypothesis is that using Virtual Reality (VR) will objectively decrease anxiety scores measured by mYPAS by five percent (primary outcome). The secondary outcome will be the parents or the legally authorized representative (LAR) subjective reports of anxiety with the use of VR. The Kind VR device is used in house at Children's Health in the Dallas and Plano campuses. The VR device used in this study qualifies as exempt from FDA IDE regulations. It is a non-significant risk, non-invasive, interactive video device the user wears like goggles. The study carries minimal risks to the subjects and is designed to minimize patient discomfort from placement or motion sickness. Furthermore, the device has disposable covers for protection against infection and can be sanitized between uses, once the disposable covers are removed. Children's Health System of Texas (CHST) and this research group are not partnering entities with the Kind VR, and the Kind VR device is not being studied. The effect of virtual reality (VR) on preprocedural anxiety as measured by questionnaires and the observations of the modified Yale Preoperative Anxiety Scale (mYPAS) is being studied Most patients coming to the Clinic of Cancer and Blood Disorders (CCBD) are under chronic care for their ongoing disease and are likely to be coming to the CCBD at least twice in a 6-month period. The CCBD schedule will be reviewed by the researchers for patients age 5-12, requiring port access at least twice during the next six-month period. Patient families whose child meets the basic screening criteria, and have no exclusion criteria, will be approached privately as possible participants in the study. Up to 100 subjects will be enrolled over a 2-year period. Once the subject/parent or LAR agrees to participate, study staff will randomize the subjects into which standard of care distraction method for anxiety management they will receive first in this study.

Detailed description

1. After the potential participants signed informed consent and were screened for the ability to participate in the study at a treatment appointment. 2. They then came to their cancer center (CCBD) appointment for port access for chemotherapy and were randomized to the Virtual Reality (VR) distraction group first, OR the Non-Virtual Reality (Non-VR) Distraction group first. 3. At this CCBD visit, they then participated in their port needle access as part of standard of care for their cancer treatment using either VR or non-VR distraction for anxiety mitigation, depending on randomization, and were observed during the needle access with the Modified Yale Pre-procedural Anxiety Scale (mYPAS) to assess anxiety during the needle access procedure. The mYPAS is an objective, validated, observational anxiety assessment tool. 4. In addition, parents were asked subjective questions as to how they thought their child tolerated Port needle access with the VR versus Non-VR accordingly. 5. The study personnel then asked when their next potential cancer center appointment for port access to schedule participation in the second arm according to their randomization stratification. In this way, each study participant served as their own control. 6. At the next possible port needle access appointment, they were once again observed using the mYPAS scale for the 2nd port access, with either VR or Non-VR distraction, depending on initial randomization group. 7. Parents were once again asked subjective questions as to how they thought their child tolerated Port needle access with the VR versus Non-VR accordingly. 8. The participants data could Only be included in the study if they participated in both study arms to completion.

Interventions

OTHERVirtual reality

Virtual reality game played during port needle access.

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

Randomized Crossover design study will be performed. Subjects will be randomized (1 to 1 randomization) at their initial encounter to either VR or Non-VR. During their second visit patients will be given the alternative mode of care (i.e. patients who initially received VR distraction will be given Non-VR distraction, and patients who initially received Non- VR distraction will receive VR distraction)

Eligibility

Sex/Gender
ALL
Age
5 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Any patient of the Children's Medical Center CCBD * 5-12 years of age * Patient requiring their port accessed twice or more within a 6 months period * Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

* Subjects younger than 5 and older than 12 * Patients requiring recovery in PICU or sites other than PACU * If parents or subject is not willing to participate * Subjects with severe developmental delays and subjects with developmental challenges preventing them from keeping the VR device on are also excluded * Patients who will not be in CCBD for port access at least twice in 6 months

Design outcomes

Primary

MeasureTime frameDescription
Preoperative Anxiety Score in Pediatric Oncology Patients2 yearsPreoperative anxiety score in pediatric oncology patients as measured by modified Yale Preoperative Anxiety Scale (mYPAS), a validated preoperative/procedural anxiety score. Possible scores range from 23 to 100. Higher score values are correlated with increased preoperative anxiety.

Secondary

MeasureTime frameDescription
Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR2 yearsNumber of parents or legally authorized representative (LAR) who subjectively report decreased anxiety in their kids (participants in this study) with the use of VR (Virtual Reality) would be calculated based on Parents' questionnaires scored and evaluated for subjective improvement in parental assessment of preoperative anxiety.

Countries

United States

Participant flow

Pre-assignment details

Out of patients who were initially enrolled in this randomized crossover design, those not randomized or didn't participate in randomization are reported in the Non-Randomized Arm in the table below.

Participants by arm

ArmCount
Non-VR (Virtual Reality), Then VR
The patient is not assigned to play the VR game. mYPAS scoring for port access is done.
26
VR (Virtual Reality), Then Non-VR
The patient is assigned to play the VR game for 15 minutes prior to actual port access procedure start. mYPAS scoring while playing VR device for Port access Virtual reality: Virtual reality game
26
Non-Randomized Patients
This group was consented but not randomized into the study.
37
Total89

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyDeath001
Overall StudyDid not participate in randomization0033
Overall StudySubject did not want to wear the VR Helmet002
Overall StudyWithdrawal by Subject001

Baseline characteristics

CharacteristicNon-VR (Virtual Reality), Then VRTotalNon-Randomized PatientsVR (Virtual Reality), Then Non-VR
Age, Categorical
<=18 years
26 Participants89 Participants37 Participants26 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants0 Participants
Diagnosed with Developmental Delay
No
24 Participants86 Participants37 Participants25 Participants
Diagnosed with Developmental Delay
Yes
2 Participants3 Participants0 Participants1 Participants
History of Claustrophobia
No
23 Participants85 Participants37 Participants25 Participants
History of Claustrophobia
Yes
3 Participants4 Participants0 Participants1 Participants
History of Motion Sickness
No
22 Participants83 Participants37 Participants24 Participants
History of Motion Sickness
Yes
4 Participants6 Participants0 Participants2 Participants
Likes Playing Video Games
No
0 Participants37 Participants37 Participants0 Participants
Likes Playing Video Games
Yes
26 Participants52 Participants0 Participants26 Participants
Number of Times of Previous Port Access Procedures
0 Times
4 Participants8 Participants0 Participants4 Participants
Number of Times of Previous Port Access Procedures
>10 Times
15 Participants32 Participants0 Participants17 Participants
Number of Times of Previous Port Access Procedures
1-3 Times
4 Participants6 Participants0 Participants2 Participants
Number of Times of Previous Port Access Procedures
4-6 Times
0 Participants1 Participants0 Participants1 Participants
Number of Times of Previous Port Access Procedures
7-9 Times
3 Participants4 Participants0 Participants1 Participants
Number of Times of Previous Port Access Procedures
Unknown or Not Reported
0 Participants38 Participants37 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants5 Participants2 Participants1 Participants
Race (NIH/OMB)
Black or African American
4 Participants15 Participants6 Participants5 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants3 Participants2 Participants1 Participants
Race (NIH/OMB)
White
20 Participants66 Participants27 Participants19 Participants
Sex: Female, Male
Female
8 Participants39 Participants23 Participants8 Participants
Sex: Female, Male
Male
18 Participants50 Participants14 Participants18 Participants
Taking Medications for Anxiety, Depression, or Agitation
No
20 Participants39 Participants0 Participants19 Participants
Taking Medications for Anxiety, Depression, or Agitation
Unknown or Not Reported
1 Participants38 Participants37 Participants0 Participants
Taking Medications for Anxiety, Depression, or Agitation
Yes
5 Participants12 Participants0 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 520 / 521 / 37
other
Total, other adverse events
3 / 522 / 520 / 37
serious
Total, serious adverse events
0 / 520 / 521 / 37

Outcome results

Primary

Preoperative Anxiety Score in Pediatric Oncology Patients

Preoperative anxiety score in pediatric oncology patients as measured by modified Yale Preoperative Anxiety Scale (mYPAS), a validated preoperative/procedural anxiety score. Possible scores range from 23 to 100. Higher score values are correlated with increased preoperative anxiety.

Time frame: 2 years

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)
Non-VR (Virtual Reality)Preoperative Anxiety Score in Pediatric Oncology PatientsHolding Phase31.44 score on a scale
Non-VR (Virtual Reality)Preoperative Anxiety Score in Pediatric Oncology PatientsInduction Phase45.38 score on a scale
Non-VR (Virtual Reality)Preoperative Anxiety Score in Pediatric Oncology PatientsChange from Holding to Induction13.94 score on a scale
VR (Virtual Reality)Preoperative Anxiety Score in Pediatric Oncology PatientsHolding Phase28.26 score on a scale
VR (Virtual Reality)Preoperative Anxiety Score in Pediatric Oncology PatientsInduction Phase32.81 score on a scale
VR (Virtual Reality)Preoperative Anxiety Score in Pediatric Oncology PatientsChange from Holding to Induction4.55 score on a scale
Secondary

Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VR

Number of parents or legally authorized representative (LAR) who subjectively report decreased anxiety in their kids (participants in this study) with the use of VR (Virtual Reality) would be calculated based on Parents' questionnaires scored and evaluated for subjective improvement in parental assessment of preoperative anxiety.

Time frame: 2 years

Population: 51 parents completed the VR experience survey, while one parent opted out of completing the survey. (Only data from parents who completed the VR experience survey have been analyzed and reported for this outcome)

ArmMeasureGroupValue (NUMBER)
Non-VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRHolding Phase : Parents Reporting VR Improved Anxiety36 participants
Non-VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRHolding Phase : Parents Reporting VR Did Not Change Anxiety15 participants
Non-VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRHolding Phase : Parents Reporting VR Worsened Anxiety0 participants
Non-VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRInduction Phase : Parents Reporting VR Improved Anxiety47 participants
Non-VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRInduction Phase : Parents Reporting VR Did Not Change Anxiety4 participants
Non-VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRInduction Phase : Parents Reporting VR Worsened Anxiety0 participants
VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRInduction Phase : Parents Reporting VR Did Not Change Anxiety4 participants
VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRHolding Phase : Parents Reporting VR Improved Anxiety36 participants
VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRInduction Phase : Parents Reporting VR Improved Anxiety47 participants
VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRHolding Phase : Parents Reporting VR Did Not Change Anxiety15 participants
VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRInduction Phase : Parents Reporting VR Worsened Anxiety0 participants
VR (Virtual Reality)Number of Parents or Legally Authorized Representative (LAR) Who Subjectively Report Decreased Anxiety With the Use of VRHolding Phase : Parents Reporting VR Worsened Anxiety0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026